Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon
Vishal Sehgal1, Sukhminder Jit Singh Bajwa2★, Rinku Sehgal3, John A Consalvo4★ Corresponding author
- 1Department of Internal Medicine, The Commonwealth Medical College.
- 2Department of Anesthesiology and Intensive Care Medicine, Gian Sagar Medical College, Patiala, Punjab, India.
- 3Department of Internal Medicine, Wright Center, College.
- 4Department of Emergency Medicine, Regional Hospital of Scranton, Scranton, Pennsylvania, USA.
CORRESPONDENCE
Sukhminder Jit Singh Bajwa
Department of Anesthesiology and Intensive Care Medicine, Gian Sagar Medical College, Patiala, Punjab, India.
Received: 22-02-2014; Revised: 27-12-2013; Accepted: 16-01-2014.
Volume 5, Issue 4 · pp. 227–231 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.142428
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Canagliflozin is the first available oral inhibitor of sodium/glucose cotransporter 2 (SGLT2) in the market. At the outset it sounds excellent for the use in the elderly diabetic population, because of its minimal tendency to cause hypoglycemia. However, the clinician needs to exercise caution as it needs to be dosed renally. The clinician needs to be circumspect about potential drug interactions, especially when there is an underlying chronic kidney disease (CKD) and congestive heart failure (CHF). Also its use is best avoided in people who are predisposed to genital mycotic and urinary tract infections (UTI).
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Sehgal, V., Bajwa, S. J. S., Sehgal, R., & Consalvo, J. A. (2014). Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon. Journal of Pharmacology and Pharmacotherapeutics, 5(4), 227–231. https://doi.org/10.4103/0976-500X.142428